Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Recruiting · NCT04925479 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT04925479 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Childrens Hospital of Philadelphia | Philadelphia | United States | 5 |
| Cinn Children Hosp Medical Center | Cincinnati | United States | 10 |
| Columbia University Medical Center New York Presbyterian | New York | United States | 3 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Indiana UH Riley H for CIU | Indianapolis | United States | 1 |
| Uni Of Texas MD Anderson Cancer Ctr | Houston | United States | 1 |
| University of Mississippi Medical Center | Jackson | United States | 2 |
| University of Utah | Salt Lake City | United States | 106 |